Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRX-3 in Progressive Chronic Kidney Disease
NCT06866236Phase 3Not yet recruiting
- Sponsor
- Ebima Clifford Okundaye
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QRX-3 in chronic kidney disease (CKD), sponsored by Ebima Clifford Okundaye. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
QRX-3
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06866236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866236.